Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Announces Co-Marketing Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry Data Analysis
Visiopharm Phenomap software presented at the Fluidigm Imaging Mass Cytometry User Group Meeting, expanding the suite of Hyperion Imaging System data analysis tools for translational and clinical research SOUTH SAN FRANCISCO, Calif. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation
View HTML
Toggle Summary Fluidigm Partners with GenomOncology to Provide a Comprehensive Immuno-Oncology Gene Expression Solution on Biomark HD
Providing a best-in-class solution for immuno-oncology research, from RNA extraction to comprehensive data analysis, to advance therapeutic development SOUTH SAN FRANCISCO, Calif. , Sept. 07, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and GenomOncology today announced an expanded
View HTML
Toggle Summary Fluidigm to Participate at Upcoming Investor Events in September
SOUTH SAN FRANCISCO, Calif. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM), a leader in mass cytometry and microfluidics technologies, announced today that the company’s management team will participate in three upcoming investor conferences in New York : Vikram Jog, Chief
View HTML
Toggle Summary Fluidigm to Host 2nd Annual Imaging Mass Cytometry User Group Meeting
Leading translational and clinical researchers to share new insights and best practices using Imaging Mass Cytometry SOUTH SAN FRANCISCO, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation , a leader in mass cytometry and microfluidics technologies, today announced it will hold its 2nd
View HTML
Toggle Summary Fluidigm Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that the Compensation Committee of its Board of Directors, which is comprised entirely of independent directors, granted equity awards effective as of July 31, 2018 , under Fluidigm's
View HTML
Toggle Summary Fluidigm Announces Second Quarter 2018 Financial Results
Total revenue increases 11 percent to $26.4 million Mass cytometry revenue growth of 32 percent Total consumables revenue growth of 19 percent SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced financial results for the second quarter
View HTML
Toggle Summary Fluidigm Introduces a Lower-Cost Workflow for Full-Length Single-Cell mRNA Sequencing on C1
Providing more affordable full-length single-cell mRNA sequencing with industry-leading coverage and sensitivity for in-depth cellular characterization SOUTH SAN FRANCISCO, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation , a leader in mass cytometry and microfluidics technologies,
View HTML
Toggle Summary Fluidigm Announces First Multimodal Single-Cell Application for the C1
Pairing epigenetic profiling with T cell receptor sequencing at single-cell resolution to advance cancer, immunology and stem cell research SOUTH SAN FRANCISCO, Calif. , July 10, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation , a leader in mass cytometry and microfluidics technologies, today
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Second Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif. , July 05, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative life science company that develops, manufactures and markets multiparameter mass cytometry and proprietary microfluidics systems used in research and applied markets, announced today
View HTML
Toggle Summary David King Joins Fluidigm as Vice President, Research and Development, Genomics
SOUTH SAN FRANCISCO, Calif. , June 26, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of David King as Vice President, Research and Development, Genomics. As a member of the executive leadership team reporting to President and CEO Chris Linthwaite , King
View HTML